Lunai Bioworks Executes $20M Transaction To Acquire Blood-Brain Barrier Delivery Technology And Central Nervous System Alzheimer's Drug Assets From Clemann Group

Lunai Bioworks, Inc. (NASDAQ:LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer's drug assets from the Clemann Group, SAS or its assignee.

The transaction is structured as Series B Convertible Preferred at a fixed conversion price of $1.50 per share, subject to a 19.9% beneficial ownership limitation. The structure contains no variable pricing or reset provisions, strengthening the Company's equity position while remaining NASDAQ compliant.